Kineret (anakinra) / SOBI - LARVOL DELTA

A phase 2 study of prophylactic intrathecal chemotherapy to prevent high-grade immune effector cell–associated neurotoxicity syndrome (ASH 2025) - "While prophylactic corticosteroids and cytokine-directed therapies like the IL-1 receptor antagonist anakinra have been explored, they carry potential risks and inconsistent efficacy...Study Design and This is a single-center, open-label, phase 2 trial evaluating the prophylactic use of IT methotrexate (12 mg), cytarabine (50 mg), and hydrocortisone (50 mg) in patients receiving standard-of-care axi-cel or brexu-cel for relapsed/refractory large cell or mantle cell lymphoma respectively...If effective, this approach could reduce the need for systemic corticosteroids, which are associated with significant morbidity. Further, prophylactic intrathecal therapy may be generalizable across existing and emerging CAR T-cell platforms, expanding eligibility to patients who might otherwise be excluded due to a high risk of neurologic toxicity."

P2 data • Acute Lymphocytic Leukemia • Brain Cancer • CNS Disorders • Epilepsy • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma

Real-world outcomes of autologous CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A single-center experience (ASH 2025) - "Twenty-two patients (73.3%) received R-CHOP as first-line chemoimmunotherapy...Two patients (6.7%) had prior anti-CD19 therapy, five (16.7%) had bendamustine exposure, and all patients received prior anti-CD20 monoclonal antibody...The most commonly used CART product was axicabtagene ciloleucel (N=28, 93%)...Tocilizumab was administered in 19 patients (63.3%), with 13 (68.4%) requiring only one dose...All ICANS patients received steroids, and four (33.3%) received anakinra...These findings affirm the safety and efficacy of autologous CD19-directed CAR T-cell therapy in routine clinical practice at a medium-sized academic institution. Continued research with larger sample sizes and extended follow-up periods is warranted to validate these results further."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

A rubric‑based comparison of code red and specialists in managing CAR‑T–Related cytokine release syndrome and icans (ASH 2025) - "Its margin was driven by a consistently protocol-level presentation—explicit monitoring schedules, predefined intervention thresholds (e.g., tocilizumab at 24 h of persistent fever), steroid regimens, ICU escalation criteria, and tertiary options (anakinra/siltuximab)—delivered in concise, highly actionable language. Conclusions A lean, expert-guided RAG system (Code Red) can outperform individual CAR-T specialists on simulated toxicity management scenarios while delivering rapid guidance. Ongoing improvement will rely on continuous user feedback and automated literature surveillance to preserve patient safety and guideline fidelity."

Cytokine release syndrome • Inflammation

Aberrant lymphocytes are associated with increased inflammatory complications following CAR-T infusion (ASH 2025) - "CAR-T products included axi-cel (Yescarta) (n=10), brexu-cel (Tecartus) (n=2), liso-cel (Breyanzi) (n=1), tisa-cel (Kymriah) (n=1), or CD19-Car_Lenti (produced by the Officina Farmaceutica of Bambino Gesù Children's Hospital) (n=2)...Associations were not found between number of aberrant lymphocytes and development of neurotoxicity (eg, ICANS) nor with doses of Tocilizumab, Dexamethasone, or Anakinra or with WBC. While the number of patients is small, presence of increased aberrant lymphocytes, as pre-classified by the Scopio full-field digital morphology platform, appears to be associated with increased inflammatory complications following CAR-T infusion, including CRS of grade ≥2 and prolonged neutropenia requiring G-CSF support. Digital morphology combined with artificial intelligence may represent a novel platform for predicting clinical outcomes in CAR-T therapy."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Rheumatology

CAR t-cell therapy-related cytokine release syndrome and neurotoxicity: Real-world outcomes from a comprehensive cancer center (ASH 2025) - "Treatment options included ciltacabtagene autoleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel...Secondary outcomes included use of tocilizumab, corticosteroids, vasopressors, anakinra, intrathecal chemotherapy, dasatinib, and thiamine; length of stay; survival at 100 days and 1 year... 53 patients were included in the study. Most patients receiving axi-cel experienced grade 1 or 2 CRS, with only three patients experiencing grade ≥3 CRS. The incidence of CRS was lower here compared to ZUMA-1 and ZUMA-5."

CAR T-Cell Therapy • Clinical • Cytokine release syndrome • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Endemic infections following CAR19-T-cell therapy: Real-life evidence in single-center in Brazil (ASH 2025) - "The incidence of infections following CAR-T therapy is influenced by regional and local factors. Screening for endemic infectious diseases is crucial for guiding prophylactic measures and ensuring timely intervention. This study highlights the high incidence of infections in patients undergoing CAR-T cell therapy, with 60.8% of patients developing infections, particularly in the early phase (within 30 days)."

Clinical • Acute Lymphocytic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CRP

Outpatient administration of idecabtagene vicleucel: Predictors of hospitalization and impact on survival outcomes (ASH 2025) - "87.5% (14/16) of these patients received tocilizumab. Grade 1 ICANS was highest severity observed in 19% (4/21) of patients, requiring treatment with steroids with or without anakinra... Outpatient administration of Ide-cel for RRMM is associated with a high incidence of early CRS and ICANS, often leading to unplanned hospitalizations. Lower baseline albumin and hemoglobin levels, along with elevated ferritin, may help identify patients at higher risk for complications. While these factors correlated with hospitalization risk, they did not predict survival in this small cohort."

Clinical • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Pneumonia • Respiratory Diseases

Early intervention in smoldering multiple myeloma: A systematic review of comparative prospective trials (ASH 2025) - "Two studies were phase I/II trials, one comparing the use of dose-escalated multipeptide PVX-410 vaccine +/- lenalidomide (R) in SMM patients, and the other comparing dose-escalated anakinra +/-Lenalidomide/dexamethasone (Rd)...Two studies were phase II RCTs; one compared Rd +/- Carfilzomib (K) in 58 high-risk SMM patients, with statistically significantly higher 3-year PFS in KRd of 94% versus Rd of 40%; p<0.001, across a median follow-up period of 34 months...The second phase II RCT included 20 intermediate- and high-risk SMM patients treated with Iberdomide (I) +/- d, with ORR of 84.6% versus 80% in the Id versus I group...One phase III RCT compared zoledronic acid +/- thalidomide in a total of 68 SMM patients, with a median TTP of 2.4 versus 1.2 years, 1-year PFS of 85% versus 55%, and 1-year ORR of 37% versus no confirmed response during the median follow-up of 5.9 years... Preliminary evidence from comparative trials suggests that early treatment of..."

Clinical • Review • Hematological Malignancies • Multiple Myeloma • Smoldering Multiple Myeloma

Anti-CD19 chimeric antigen receptor T-cells therapy (CAR-T) is effective in secondary cns lymphoma (SCNSL) refractory to high-dose methotrexate (HDMTX)-based chemotherapy (ASH 2025) - " 23 pts were referred to holding: 6 partial-brain irradiation, 4 intrathecal CHT, 2 polatuzumab vedotin, 5 ibrutinib, 1 HD-ifosfamide-based CHT, 2 MATRix regimen, 1 thiotepa-based ASCT, combinations of these strategies in 2...Only one pt experienced G3-4 CRS, all CRS cases were successfully treated with tocilizumab and steroids, anakinra was used in 2 cases... Varied presentation and high aggressivity of SCNSL impede the use of a uniform treatment for these pts. SCNSL refractory to HDMTX-based polyCHT can benefit significantly from a tailored multimodal holding based on the pt's history and extension of disease. Only pts with good PS and responsive to holding therapy should be offered CAR-T to avoid superfluous toxicity."

CAR T-Cell Therapy • B Cell Lymphoma • CNS Disorders • CNS Lymphoma • Epilepsy • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Secondary Central Nervous System Lymphoma

Initial experience with anti-CD19 CAR-T cell therapy in patients with Relapsed/Refractory diffuse large B-cell lymphoma in a brazilian cancer center (ASH 2025) - "Tocilizumab use was similar. ICANS was more frequent with axi-cel (75%), leading to greater Anakinra use (50%), while 72% of tisa-cel patients had no ICANS... This Brazilian real-world analysis demonstrates that both CAR-T products are feasible but differ in efficacy and toxicity. Tisa-cel showed superior early responses despite higher-risk disease, while axi-cel was associated with more neurologic toxicity and early mortality. However, it is important to highlight the limitations of our data, considering the small sample size, missing follow-up registries and the heterogeneity in baseline characteristics, precluding a robust comparative analysis between products."

CAR T-Cell Therapy • Clinical • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Anakinra for hemophagocytic lymphohistiocytosis: A real-world, multicenter retrospective study on efficacy, safety, and response durability (ASH 2025) - "Current standard etoposide-based chemotherapy regimens can control the disease, but their significant toxicities limit clinical use, especially in patients with poorer fitness or contraindications, so there is an urgent clinical need for safer, more rapidly-acting targeted treatment options. Anakinra can rapidly control disease progression and significantly reduce steroid use in real-world treatment of HLH, demonstrating good short-term efficacy. However, the duration of remission is short, suggesting that combination therapy or prolonged use may be necessary to consolidate efficacy. Although the sample size is limited and the study is retrospective, this research provides important reference for the clinical application of Anakinra in the treatment of HLH."

Real-world • Real-world evidence • Retrospective data • Hemophagocytic lymphohistiocytosis • Immunology • Inflammation • Rare Diseases

Steroid-sparing use of anakinra for secondary hemophagocytic lymphohistiocytosis in sickle cell disease with multiorgan failure – a case report (ASH 2025) - "Management included intubation and ventilation, vasopressor support, and intravenous heparin. This therapeutic choice is supported by emerging evidence favoring IL-1 blockade as a safer immunomodulatory strategy in selected ICU patients with features suggestive of HLH. Our case adds to the growing body of literature advocating for early identification of HLH in SCD patients with unremitting systemic inflammation and organ dysfunction."

Case report • Clinical • Acute Kidney Injury • Cardiovascular • Dyslipidemia • Genetic Disorders • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Hepatology • Hypertriglyceridemia • Hypotension • Immunology • Inflammation • Liver Failure • Metabolic Disorders • Nephrology • Pulmonary Embolism • Rare Diseases • Renal Disease • Respiratory Diseases • Sickle Cell Disease • IL2RA

A single center review of secondary hemophagocytic lymphohistiocytosis treatment and outcomes. (ASH 2025) - "Initial therapy was malignancy-specific chemotherapy (39%), HLH-94 protocol based therapy (30%), steroids alone (23%), and anakinra (2%) while others were not treated (6%)...Overall, 46% of patients required several lines of treatment and were subsequently treated with several additional agents in the second line setting including malignancy directed therapy, ruxolitinib, alemtuzumab, eculizumab, IVIG, cyclosporine, tacrolimus and rituximab...To improve timely diagnosis and treatment decisions, we, like other centers, are implementing electronic medical record order sets for HLH diagnosis and management and organizing an HLH expert panel to provide timely case reviews and treatment recommendations. In memory of our esteemed colleague and co-author Stephen Njau, MD"

Clinical • Review • Dyslipidemia • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hypertriglyceridemia • Immunology • Infectious Disease • Rare Diseases • Solid Tumor • IL2RA • ISG20

Clonoseq MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma. (ASH 2025) - " We retrospectively analyzed 171 MM patients treated with SOC BCMA CAR-T, idecabtagenevicleucel (110/171) and ciltacabtagene autoleucel (cilta-cel), at Moffitt Cancer Center from May 2021 toSeptember 2024 who had trackable clonotype and D90 NGS-MRD testing...Rates ofcytokine release syndrome, immune effector cell-associated neurotoxicity (ICANS), non-ICANSneurotoxicity, steroid, tocilizumab or anakinra use, intensive care unit admission, and hospital stay werecomparable between groups... In this large SOC cohort of MM patients, NGS-MRD negativity at D90 post BCMA CAR-T wasindependently associated with improved PFS and OS. Our data support the use of D90 NGS-based MRDtesting as a prognostic tool for survival outcomes and the development of MRD-driven interventions postCAR-T."

CAR T-Cell Therapy • Clinical • IO biomarker • Minimal residual disease • Hematological Malignancies • Multiple Myeloma

Real world experience of anakinra for the treatment of immune effector cell-associated neurotoxicity syndrome in large B-cell lymphoma (ASH 2025) - "Thirty-six (85.7%) patients received axicabtageneciloleucel, 4 (9.5%) lisocabtagene maraleucel and 2 (4.8%) tisagenlecleucel...Thirty-nine(92.9%) patients received corticosteroids prior to anakinra, with a median cumulative dexamethasoneequivalent dose of 40.0 mg (range 0-1041.9 mg); 95.2% received additional corticosteroids after initiationof anakinra, with a median cumulative dexamethasone equivalent of 585.0 mg (range 0-2432.1 mg)...The use of anakinra was associated with a high response rate,responses being more likely in patients with low inflammatory biomarkers, and with a decrease inproportion of deaths attributable to CRS/ICANS. Larger prospective studies are needed to better optimizepatient selection and use of anakinra in patients with CART-associated toxicities, and to potentiallyfacilitate formal approval of this agent, currently used off-label."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Rheumatology • CRP

Real-world experience with varnimcabtagene autoleucel (murine CD19 CAR-T) from India: A step towards enhanced patient access with excellent safety and efficacy (ASH 2025) - "Tocilizumab, steroids and anakinra usage was in 39%, 9% and 4% respectively. The real-world experience provides strong evidence of efficacy and safety of varnim-cel in B-NHL comparable with pivotal study. It also proves the robustness of trans-national ultracold chainlogistics, safe and effective clinical delivery and management systems for commercial rollout acrossmultiple centres in India to provide equitable access in South Asia."

Preclinical • Real-world • Real-world evidence • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Thrombocytopenia

Intrathecal chemotherapy for management of immune effector cell-associated neurotoxicity syndrome (ICANS): A multi-center, real-world analysis of clinical outcomes (ASH 2025) - "IT regimens included hydrocortisone(HC) alone in 14% and HC plus methotrexate, cytarabine, or both in the remainder.ICANS recovery did not differ significantly between IT and systemic‑only pts (83% vs 93%)...The benefit of anakinra remains uncertain given increased infectious risk and worsesurvival in high-grade ICANS. Together, the findings of this study support IT therapy as a potentialstrategy for CS‑refractory, high‑grade ICANS and underscore the need for large‑scale prospective trials toclarify the role of CSF‑directed IT steroids and/or chemotherapy."

Clinical • Clinical data • Real-world • Real-world evidence • B Cell Lymphoma • CNS Disorders • Epilepsy • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India. (ASH 2025) - "Background : Talicabtagene autoleucel (Tali-cel), a second-generation, humanized CAR-T cell therapytargeting CD19, was approved in India in October 2023 for the treatment of relapsed or refractory (r/r) B-cell malignancies...Mostpatients had received a median of 2 prior treatment lines (range: 1–7), including polatuzumab (14%), andstem cell transplantation (4%)...Tocilizumab was administered in 63%patients who developed CRS with median dose of 1 (range 1-3)...IVIG support was required in 34% patients and anakinra formanagement of IEC-HS was required 75% respectively...This real-world analysis demonstrates that tali-cel is a practical, effective, and well-tolerated treatmentoption for r/r B-NHL in India. As the first large-scale, multicenter evaluation of this therapy in the Indianhealthcare landscape, our findings support its broader implementation across various levels of clinicalpractice."

Clinical • Real-world • Real-world evidence • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Lymphoma • Non-Hodgkin’s Lymphoma

Beyond the trial: Real-world CRS, icans, and healthcare burden of CAR T-cell therapy across US oncology practices (ASH 2025) - "Ptsreceived the following CRS/ICANS treatment(s) across diseases: tocilizumab (64%-82%),dexamethasone (40%-89%), anakinra (5.5%-22%), methylprednisolone (1.9%-14%),siltuximab (0.9%-4.1%).Hospitalization rate after CAR T was 51% of DLBCL, 69% of MCL, 56% of MM. In this rw study of over 2,500 pts with DLBCL, MCL, and MM treated with CAR T, theprevalence and severity of CRS/ICANS were generally consistent with clinical trials, with a notable declinein grade >3 events over time in DLCBL. Majority of pts were treated in the inpatient setting and atacademic centers, though a meaningful proportion received CAR T in the outpatient setting (8-18%) or atcommunity practices (5-13%), reflecting increased diversity in care delivery. Across disease cohorts, ptswith grade >3 CRS had more than double ICU-level care compared to pts with lower-grade events,reflecting the substantial HCRU burden associated with severe toxicities."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Reimbursement • US reimbursement • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

Torque teno virus in pediatric CAR-T recipients (ASH 2025) - "Cytokine release syndrome (CRS) occurred in 85.2% patients (median 3 days, [1,6.5]), ICANS in 29.6%(mean 8.13 days, SD 2.6), and hemophagocytic lymphohistiocytosis (HLH) in 37% (mean 8 days, SD 2.6).Tocilizumab was administered in 40.7%, siltuximab in 29.6%, steroids in 48.1%, and anakinra in 33.3%cases. We found no associations with CARTflow subsets. CONCLUSIONSIn pediatric CART recipients, TTV-VL does not correlate with CART monitoring methods, but could predicttoxicity and outcomes."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Developmental Disorders • Diffuse Large B Cell Lymphoma • Genetic Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Human Immunodeficiency Virus • Immunology • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Pediatrics • Rare Diseases

Phase 1 clinical trial of point-of-care manufactured, fully human anti-CD19 CAR-T cells for treatment of Relapsed/Refractory lymphoid malignancies (ASH 2025) - "Patients received lymphodepletion with cyclophosphamide 60mg/kg on day -6 and fludarabine25mg/m2/day on days -5 to -3...Cytokine release syndrome (CRS) severity was noted as grade 1 (n=1), grade 2 (n=7) and grade 3 (n=1).Grade 2 CRS was treated with tocilizumab and grade 3 CRS with tocilizumab and anakinra... AntiCD19 CAR T cells with a fully human antigen recognition domain have acceptable safetyand clinical activity against R/R B cell malignancies. Point of care manufacture and fresh infusion result inrapid access to this therapy. This novel construct and manufacturing process represent a platform forfuture development of innovative cellular therapies."

CAR T-Cell Therapy • Clinical • P1 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Chronic Lymphocytic Leukemia • CNS Disorders • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Splenic Marginal Zone Lymphoma • Waldenstrom Macroglobulinemia • CD8

Talquetamab in Relapsed/Refractory multiple myeloma with renal impairment: A quaternary cancer center experience (ASH 2025) - "No significant difference in tocilizumab, steroid, or anakinra use for treatment betweengroups. Despite a higherburden of high-risk cytogenetics, the RI cohort exhibited deeper responses, reflected by significantlyhigher rates of ≥CR and PFS compared to those in the No RI cohort. These findings position talquetamabas a viable treatment option for RI patients who have been traditionally excluded from clinical trials.Prospective studies are warranted to validate these observations and confirm their inclusion in futureprospective trials to maximize benefits in real-world settings."

Gene Therapies • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology • Renal Disease

Real-world analysis of ICI-associated HLH reveals early mortality despite standard interventions (ASH 2025) - "Despite similar baselinecharacteristics after matching, treatment patterns were different between the cohorts: steroiduse was significantly lower in ICI-HLH (26% vs. 58%), which may reflect both clinical hesitation touse immunosuppressants early in ICI therapy and the rapid decline observed in these patients.At 7 days, ICI-HLH patients receiving etoposide, tocilizumab, or anakinra had significantly worsesurvival (HR 5.26, 95% CI 1.50–18.46, p=0.004), indicating that escalation therapies often begantoo late to affect outcomes...Dexamethasone alone was not significantlydifferent (HR 0.50, 95% CI 0.17–1.46), and trended toward improved survival in ICI-HLH, furthersupporting the benefit of early intervention.At 30 days, overall survival was significantly worse in the ICI-HLH group (HR 2.59, 95% CI 1.14–5.87, p=0.018)... ICI-HLH represents a distinct and rapidly progressive form of HLH. While standardtherapies—including corticosteroids and cytokine-targeting agents—appear..."

Clinical • Real-world • Real-world evidence • Hemophagocytic lymphohistiocytosis • Immunology • Rare Diseases

Early use of talicabtagene autoleucel in r/r B-acute lymphoblastic leukemia is cost-effective: Improved efficacy, reduced toxicity and healthcare resource utilization support affordable access (ASH 2025) - "Utilization of tocilizumab(72% vs. 62%), anakinra (26% vs. 24%), and IVIG (49% vs. 54%) was similar between groups, reflectingconsistent supportive management.Cost modelling revealed a 60% reduction in median hospitalization costs for early-relapse patients, drivenby shorter hospital stay, less ICU need, and fewer high-grade toxicities requiring intensive management.In this real-world cohort, patients with early relapse r/r B-ALL treated with tali-cel achieved more durableresponses, with higher remission rates and longer progression-free survival compared to those treatedlater in the disease course. In this real-world cohort, patients with early relapse r/r B-ALL treated with tali-cel achieved more durableresponses, with higher remission rates and longer progression-free survival compared to those treatedlater in the disease course. Importantly, early use was associated with lower toxicity, reduced healthcareresource utilization, and a significant reduction in overall..."

Clinical • Cost effectiveness • HEOR • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Leukemia

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients (ASH 2025) - "The most common CAR T-cell products wereaxicabtagene ciloleucel (n = 31, 25%), brexucabtagene autoleucel (n = 26, 21%), and tisagenlecleucel (n =21, 17%)...Nearly all (n = 123; 99%) patients received concurrent dexamethasone (dex) with a median totaldose of 234 mg (range, 30-690)...Sixteen patients (13%)received additional therapies, including ruxolitinib (n = 1), siltuximab (n = 3), cetuximab (n = 1), intrathecalchemotherapy (n = 11), and dasatinib (n = 1)...Higher dex doses remainedassociated with shorter time to ICANS resolution, highlighting that corticosteroids remain thecornerstone of treating refractory ICANS. More effective strategies for anakinra-refractory ICANS arecritically needed."

CAR T-Cell Therapy • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma